The White House announced that starter doses of the much-anticipated weight-loss pills from Eli Lilly and Novo Nordisk—once approved—will be priced at $149 per month for Medicare and Medicaid beneficiaries, as well as for cash-paying customers through the new direct-to-consumer TrumpRx platform.
According to the Food and Drug Administration, both drugs are being reviewed under a new expedited approval process that could shorten the typical timeline by several months.
Lilly CEO David Ricks said the company now anticipates regulatory approval for its obesity medication, orforglipron, in the first quarter of next year, aligning with the launch of the government’s Medicare pricing pilot.
The White House announced that the new price reductions will take effect by January for cash-paying customers, by mid-2026 for Medicare recipients, and gradually for Medicaid enrollees as states opt into the program.
For currently available injectable GLP-1 drugs used to treat diabetes and other approved conditions, government costs will drop to $245 per month for Medicare and Medicaid patients.
Through the TrumpRx website—accessible to all Americans—the average monthly price for both injectable and pill versions will start at or below $350 and is expected to decrease to around $245 within two years.
Eli Lilly confirmed that under the new pricing deal, the lowest dos
